HUTCHMED (NASDAQ:HCM) Sets New 52-Week Low – Should You Sell?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $10.40 and last traded at $10.5310, with a volume of 13101 shares changing hands. The stock had previously closed at $10.83.

Analyst Ratings Changes

HCM has been the subject of several research analyst reports. Bank of America cut their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 10th. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 1st. Finally, Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $16.80.

HUTCHMED Stock Down 3.0%

The company has a 50 day moving average price of $13.02 and a 200 day moving average price of $13.91. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. XY Capital Ltd grew its stake in shares of HUTCHMED by 291.1% during the third quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock worth $831,000 after purchasing an additional 39,266 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of HUTCHMED by 157.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock worth $746,000 after purchasing an additional 34,248 shares during the period. Bank of America Corp DE grew its stake in shares of HUTCHMED by 5.9% during the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after purchasing an additional 1,209 shares during the period. BNP Paribas Financial Markets grew its stake in shares of HUTCHMED by 19.7% during the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after purchasing an additional 4,116 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares during the period. 8.82% of the stock is currently owned by institutional investors.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.